GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00300105 | Stomach | GC | establishment of cell polarity | 20/1159 | 143/18723 | 5.20e-04 | 7.33e-03 | 20 |
GO:00030143 | Stomach | GC | renal system process | 16/1159 | 110/18723 | 1.19e-03 | 1.37e-02 | 16 |
GO:0006857 | Stomach | GC | oligopeptide transport | 5/1159 | 16/18723 | 2.21e-03 | 2.18e-02 | 5 |
GO:20006496 | Stomach | GC | regulation of sodium ion transmembrane transporter activity | 10/1159 | 58/18723 | 2.73e-03 | 2.52e-02 | 10 |
GO:00101555 | Stomach | GC | regulation of proton transport | 6/1159 | 24/18723 | 2.85e-03 | 2.58e-02 | 6 |
GO:19023056 | Stomach | GC | regulation of sodium ion transmembrane transport | 11/1159 | 68/18723 | 2.89e-03 | 2.61e-02 | 11 |
GO:0070293 | Stomach | GC | renal absorption | 5/1159 | 17/18723 | 2.98e-03 | 2.66e-02 | 5 |
GO:00085443 | Stomach | GC | epidermis development | 33/1159 | 324/18723 | 3.43e-03 | 2.96e-02 | 33 |
GO:00099134 | Stomach | GC | epidermal cell differentiation | 23/1159 | 202/18723 | 3.50e-03 | 3.02e-02 | 23 |
GO:00434096 | Stomach | GC | negative regulation of MAPK cascade | 21/1159 | 180/18723 | 3.86e-03 | 3.26e-02 | 21 |
GO:00109594 | Stomach | GC | regulation of metal ion transport | 39/1159 | 406/18723 | 4.34e-03 | 3.58e-02 | 39 |
GO:20012353 | Stomach | GC | positive regulation of apoptotic signaling pathway | 16/1159 | 126/18723 | 4.84e-03 | 3.87e-02 | 16 |
GO:0051896 | Stomach | GC | regulation of protein kinase B signaling | 21/1159 | 185/18723 | 5.30e-03 | 4.15e-02 | 21 |
GO:00601192 | Stomach | GC | inner ear receptor cell development | 8/1159 | 45/18723 | 5.84e-03 | 4.44e-02 | 8 |
GO:190260011 | Stomach | CAG with IM | proton transmembrane transport | 34/1050 | 157/18723 | 7.15e-12 | 2.38e-09 | 34 |
GO:200123311 | Stomach | CAG with IM | regulation of apoptotic signaling pathway | 52/1050 | 356/18723 | 2.17e-10 | 3.85e-08 | 52 |
GO:009719311 | Stomach | CAG with IM | intrinsic apoptotic signaling pathway | 42/1050 | 288/18723 | 1.25e-08 | 1.05e-06 | 42 |
GO:002260411 | Stomach | CAG with IM | regulation of cell morphogenesis | 41/1050 | 309/18723 | 2.63e-07 | 1.61e-05 | 41 |
GO:200124211 | Stomach | CAG with IM | regulation of intrinsic apoptotic signaling pathway | 27/1050 | 164/18723 | 4.39e-07 | 2.43e-05 | 27 |
GO:003252811 | Stomach | CAG with IM | microvillus organization | 9/1050 | 24/18723 | 3.22e-06 | 1.29e-04 | 9 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
SLC9A3 | SNV | Missense_Mutation | | c.2153N>T | p.Ser718Leu | p.S718L | P48764 | protein_coding | tolerated(0.06) | benign(0) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
SLC9A3 | SNV | Missense_Mutation | | c.838A>C | p.Lys280Gln | p.K280Q | P48764 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-AR-A0TS-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | SD |
SLC9A3 | SNV | Missense_Mutation | | c.917N>G | p.Leu306Arg | p.L306R | P48764 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-C8-A134-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | 5-fluorouracil | CR |
SLC9A3 | SNV | Missense_Mutation | | c.688G>A | p.Val230Met | p.V230M | P48764 | protein_coding | tolerated(0.25) | possibly_damaging(0.82) | TCGA-E9-A244-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cyclophosphamide | SD |
SLC9A3 | deletion | Frame_Shift_Del | novel | c.978delN | p.Asn326LysfsTer14 | p.N326Kfs*14 | P48764 | protein_coding | | | TCGA-D8-A27V-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | tamoxiphen | SD |
SLC9A3 | SNV | Missense_Mutation | novel | c.1250C>T | p.Ala417Val | p.A417V | P48764 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
SLC9A3 | SNV | Missense_Mutation | rs755154955 | c.2048N>A | p.Arg683Gln | p.R683Q | P48764 | protein_coding | deleterious(0.03) | benign(0.129) | TCGA-EK-A2PM-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD |
SLC9A3 | SNV | Missense_Mutation | novel | c.782N>A | p.Gly261Asp | p.G261D | P48764 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-VS-A9UJ-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
SLC9A3 | insertion | Frame_Shift_Ins | novel | c.2031_2032insA | p.Ala678SerfsTer50 | p.A678Sfs*50 | P48764 | protein_coding | | | TCGA-DG-A2KH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
SLC9A3 | SNV | Missense_Mutation | | c.287N>A | p.Gly96Asp | p.G96D | P48764 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | | GLUCOCORTICOID | | 9727362 |
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | | AZD1722 | | |
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | inhibitor | CHEMBL2107782 | | |
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | | AVE-0657 | | |
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | | AZD1772//RDX5791 | | |
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | inhibitor | CHEMBL3301627 | TENAPANOR HYDROCHLORIDE | |
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | | RDX-5791 | TENAPANOR HYDROCHLORIDE | |
6550 | SLC9A3 | DRUGGABLE GENOME, TRANSPORTER, CELL SURFACE, EXCHANGER | | ALBUMIN | ALBUMIN HUMAN | 11251045,11698229 |